Odyssey Therapeutics, Inc.
ODTX
NASDAQ Global Market17.55
USD
-0.03
- -
CIK
0001882782
ISIN
US67613T1043
CUSIP
67613T104
Return %
Stock
S&P500
1Y
6.88
19.01
3Y
6.88
65.49
5Y
6.88
72.21
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Gary D. Glick
- Full Time Employees
- 100
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 51 Sleeper Street Boston MA United States of America 02210
- IPO Date
- May 8, 2026
- CIK
- 0001882782
- Website
- odysseytx.com
- Similar Companies
- Business
- Odyssey Therapeutics, Inc. engages in the discovery and development of precision immunology therapies targeting autoimmune and inflammatory diseases, leveraging small molecule and protein therapeutic modalities to modulate upstream inflammatory signaling with a focus on the innate immune system. The company is headquartered in Boston, Massachusetts, and operates primarily in the United States with ongoing worldwide collaboration potential as it advances its pipeline. Main products and services: - Therapeutic discovery and development services: research and development for small molecules and protein therapeutics designed to modulate key inflammatory signaling nodes; target validation, lead optimization, preclinical testing, and translational biology support. - RIPK2 inhibitors programs: oral small-molecule inhibitors targeting RIPK2 for inflammatory diseases such as inflammatory bowel disease, including monotherapy and combination therapy development; early-stage clinical data generation and readiness for Phase 2 objectives. - SLC15A4–targeted therapeutics: protein/peptide-based or small-molecule approaches aimed at modulation of innate immune signaling pathways associated with autoimmunity; preclinical and early clinical advancement. - Pipeline compounds across immunology segments: additional internal programs focusing on upstream nodal targets within innate and adaptive immune pathways, designed to achieve disease modification with improved safety profiles. Latest major company changes: - Financing and fundraising: completes a notable Series D round to support broad clinical proof-of-concept studies across multiple autoimmune and inflammatory programs, expanding the clinical and preclinical portfolio and accelerating pipeline progression. - Clinical milestones and data readouts: advances lead RIPK2 inhibitor into ongoing Phase 2 evaluations for ulcerative colitis with anticipated topline data for monotherapy and follow-on data for combination regimens; execution of plans to broaden clinical proof-of-concept across additional indications within immunology. - Strategic partnerships and collaborations: pursues strategic alliances and collaborations to advance its technological platforms and to expand access to late-stage development capabilities and potential combination therapy opportunities. - Product launches and pipeline expansion: ongoing expansion of the pipeline to include additional immunology targets beyond RIPK2, with continued emphasis on selecting targets with robust disease biology and large patient populations. Additional context: - Industry and business segments: biotechnology; immunology; autoimmune and inflammatory diseases; therapeutic discovery and development; early- to mid-stage clinical development. - Target markets and customer types: pharmaceutical partners, biotechnology collaborators, research institutions, and eventually patients through clinical programs and potential future commercialization. - Geographic operations: primarily based in the United States with activities and partnerships that may span global markets; headquarters in the Boston area with clinical operations and research activities in the U.S. and potential international collaborations. - Founding year and headquarters: founded in the 2010s; headquarters established in the United States (Boston-area focus). - Subsidiaries or parent relations: operates as an independent biotechnology company with potential strategic partnerships and licensing arrangements; no explicit parent company disclosed. Note: Odyssey Therapeutics focuses on delivering disease-modifying therapies by precisely targeting inflammatory signaling nodes, aiming to improve patient outcomes in autoimmune conditions through a convergent pipeline of small molecules and protein therapeutics. The company’s latest funding and clinical advancement underscore its commitment to expanding therapeutic options for unmet needs in immunology.
Odyssey Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
First Look: eBay rebuffs GME, oil swings, CEOs to China
Healthcare IPOs Raise $4.7 Billion As Odyssey, Mobia Debuts Slip
Odyssey Therapeutics Announces Pricing of Upsized Initial Public Offering
Odyssey Therapeutics Appoints Jolie M. Siegel as Executive Vice President, General Counsel
Odyssey Therapeutics Appoints Dennis Dean, Ph.D., as Executive Vice President, Head of Non-Clinical Development
Odyssey Therapeutics Appoints Pharmaceutical Leader Nia Tatsis, Ph.D., to Its Board of Directors
Jeito Capital announces significant participation in oversubscribed $213M Series D financing for Odyssey Therapeutics to advance clinical pipeline addressing autoimmune diseases with high unmet needs
Odyssey Therapeutics Announces Oversubscribed $213 Million Series D Financing to Advance Clinical Pipeline for Autoimmune Diseases
U.S. IPO Weekly Recap: IPO Calendar Slows Down With Small Listings
U.S. IPO Weekly Recap: Active January Closes Out With Several Sizable IPOs
Odyssey Therapeutics Begins IPO Rollout